• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对于需要新生血管形成的外周微血管病变,羟苯磺酸钙能否安全使用?

Can calcium dobesilate be used safely for peripheral microvasculopathies that require neoangiogenesis?

作者信息

Demirtas Sinan, Caliskan Ahmet, Guclu Orkut, Yazici Suleyman, Karahan Oguz, Yavuz Celal, Mavitas Binali

机构信息

Department of Cardiovascular Surgery, Medical School of Dicle University, Diyarbakir, Turkey.

出版信息

Med Sci Monit Basic Res. 2013 Sep 27;19:253-7. doi: 10.12659/MSMBR.889427.

DOI:10.12659/MSMBR.889427
PMID:24072135
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3808185/
Abstract

BACKGROUND

Calcium dobesilate (CaD) is a member of the synthetic veno-active drug family. Only a small number of reports are available that describe the micro-angiogenic effects of CaD in the current literature.

MATERIAL AND METHODS

The antiangiogenic potential of CaD was compared with bevacizumab (Bb), which is a potent angiogenesis inhibitor, in a chick chorioallantoic membrane model. Four different concentrations (10-7, 10-6, 10-5, and 10-4 M) of drug pellet were prepared for each drug. Changes in vessel formation were scored and compared for each drug according to the previous literature.

RESULTS

The antiangiogenic behavior of CaD was lower than Bb, despite the significant dose-dependent manner of escalation. The anti-angiogenic scores of CaD were determined as 0.20, 0.47, 0.66, 1.0 in 10-7, 10-6, 10-5, and 10-4 M concentrations, respectively (average score >0.5 was significant).

CONCLUSIONS

According to the data obtained, this agent should be used carefully for cases in which angiogenesis plays an important role in healing.

摘要

背景

羟苯磺酸钙(CaD)是合成的静脉活性药物家族的一员。在当前文献中,仅有少数报告描述了CaD的微血管生成作用。

材料与方法

在鸡胚绒毛尿囊膜模型中,将CaD的抗血管生成潜力与强效血管生成抑制剂贝伐单抗(Bb)进行比较。为每种药物制备四种不同浓度(10-7、10-6、10-5和10-4 M)的药粒。根据先前文献,对每种药物的血管形成变化进行评分并比较。

结果

尽管CaD具有显著的剂量依赖性升高方式,但其抗血管生成行为低于Bb。CaD在10-7、10-6、10-5和10-4 M浓度下的抗血管生成评分分别确定为0.20、0.47、0.66、1.0(平均评分>0.5具有显著性)。

结论

根据所获得的数据,对于血管生成在愈合中起重要作用的病例,应谨慎使用该药物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/181b/3808185/b43b04a929e0/medscimonitbasicres-19-253-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/181b/3808185/d3b44be7019e/medscimonitbasicres-19-253-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/181b/3808185/d377d7b92087/medscimonitbasicres-19-253-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/181b/3808185/3f3830b35620/medscimonitbasicres-19-253-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/181b/3808185/b43b04a929e0/medscimonitbasicres-19-253-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/181b/3808185/d3b44be7019e/medscimonitbasicres-19-253-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/181b/3808185/d377d7b92087/medscimonitbasicres-19-253-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/181b/3808185/3f3830b35620/medscimonitbasicres-19-253-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/181b/3808185/b43b04a929e0/medscimonitbasicres-19-253-g004.jpg

相似文献

1
Can calcium dobesilate be used safely for peripheral microvasculopathies that require neoangiogenesis?对于需要新生血管形成的外周微血管病变,羟苯磺酸钙能否安全使用?
Med Sci Monit Basic Res. 2013 Sep 27;19:253-7. doi: 10.12659/MSMBR.889427.
2
Dobesilate is an angiogenesis inhibitor.羟苯磺酸钙是一种血管生成抑制剂。
Eur J Med Res. 2005 Sep 12;10(9):369-72.
3
The antiangiogenic effects of levosimendan in a CAM assay.左西孟旦在鸡胚尿囊膜血管生成抑制试验中的抗血管生成作用。
Microvasc Res. 2012 May;83(3):263-6. doi: 10.1016/j.mvr.2012.01.002. Epub 2012 Jan 18.
4
Calcium Dobesilate and Micro-vascular diseases.羟苯磺酸钙与微血管疾病。
Life Sci. 2019 Mar 15;221:348-353. doi: 10.1016/j.lfs.2019.02.023. Epub 2019 Feb 12.
5
Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.VHL 缺失型透明细胞肾细胞癌中具有内皮窗孔的肿瘤微血管是抗血管生成治疗的有效靶点。
Cancer Sci. 2012 Nov;103(11):2027-37. doi: 10.1111/j.1349-7006.2012.02412.x. Epub 2012 Oct 10.
6
(99)mTc-(CO)(3) His-annexin A5 micro-SPECT demonstrates increased cell death by irinotecan during the vascular normalization window caused by bevacizumab.(99)mTc-(CO)(3) His-annexin A5 微 SPECT 显示贝伐单抗引起的血管正常化窗口期间伊立替康导致细胞死亡增加。
J Nucl Med. 2011 Nov;52(11):1786-94. doi: 10.2967/jnumed.111.092650.
7
Inhibition of vascular endothelial growth factor (VEGF)-induced endothelial proliferation, arterial relaxation, vascular permeability and angiogenesis by dobesilate.羟苯磺酸钙抑制血管内皮生长因子(VEGF)诱导的内皮细胞增殖、动脉舒张、血管通透性和血管生成。
Eur J Pharmacol. 2011 Sep 30;667(1-3):153-9. doi: 10.1016/j.ejphar.2011.06.015. Epub 2011 Jun 22.
8
Antiangiogenic agents: fueling cancer's hypoxic roots.抗血管生成药物:滋养癌症的缺氧根源。
Cell Cycle. 2012 Apr 1;11(7):1265-6. doi: 10.4161/cc.19890.
9
Antiangiogenic therapy for high-grade glioma.高级别胶质瘤的抗血管生成治疗
Cochrane Database Syst Rev. 2014 Sep 22(9):CD008218. doi: 10.1002/14651858.CD008218.pub3.
10
Antiangiogenic therapy for cancer: an update.癌症的抗血管生成治疗:最新进展。
Pharmacotherapy. 2012 Dec;32(12):1095-111. doi: 10.1002/phar.1147.

引用本文的文献

1
Investigation of the Antiangiogenic Properties of Zoledronic Acid by Using Chorioallantoic Membrane Model.利用鸡胚绒毛尿囊膜模型研究唑来膦酸的抗血管生成特性。
Dose Response. 2022 Apr 27;20(2):15593258221093410. doi: 10.1177/15593258221093410. eCollection 2022 Apr-Jun.
2
Calcium dobesilate may alleviate diabetes‑induced endothelial dysfunction and inflammation.羟苯磺酸钙可能缓解糖尿病引起的内皮功能障碍和炎症。
Mol Med Rep. 2017 Dec;16(6):8635-8642. doi: 10.3892/mmr.2017.7740. Epub 2017 Oct 9.
3
Non-traditional systemic treatments for diabetic retinopathy: an evidence-based review.

本文引用的文献

1
Comparison of the antiangiogenic effects of heparin sodium, enoxaparin sodium, and tinzaparin sodium by using chorioallantoic membrane assay.采用鸡胚绒毛尿囊膜试验比较肝素钠、依诺肝素钠和替扎肝素钠的抗血管生成作用。
Blood Coagul Fibrinolysis. 2012 Apr;23(3):218-21. doi: 10.1097/MBC.0b013e3283504132.
2
The antiangiogenic effects of levosimendan in a CAM assay.左西孟旦在鸡胚尿囊膜血管生成抑制试验中的抗血管生成作用。
Microvasc Res. 2012 May;83(3):263-6. doi: 10.1016/j.mvr.2012.01.002. Epub 2012 Jan 18.
3
Inhibition of vascular endothelial growth factor (VEGF)-induced endothelial proliferation, arterial relaxation, vascular permeability and angiogenesis by dobesilate.
糖尿病视网膜病变的非传统全身治疗:一项基于证据的综述。
Curr Med Chem. 2015;22(21):2580-9. doi: 10.2174/0929867322666150520095923.
羟苯磺酸钙抑制血管内皮生长因子(VEGF)诱导的内皮细胞增殖、动脉舒张、血管通透性和血管生成。
Eur J Pharmacol. 2011 Sep 30;667(1-3):153-9. doi: 10.1016/j.ejphar.2011.06.015. Epub 2011 Jun 22.
4
Calcium dobesilate in patients suffering from chronic venous insufficiency: a double-blind, placebo-controlled, clinical trial.羟苯磺酸钙治疗慢性静脉功能不全患者:一项双盲、安慰剂对照临床试验
Phlebology. 2011 Jun;26(4):162-8. doi: 10.1258/phleb.2010.010051. Epub 2011 Apr 7.
5
Calcium dobesilate and oxerutin: effectiveness of combination therapy.羟苯磺酸钙和奥昔芦丁:联合治疗的有效性。
Phlebology. 2010 Apr;25(2):66-71. doi: 10.1258/phleb.2009.008085.
6
Endothelial function impairment in chronic venous insufficiency: effect of some cardiovascular protectant agents.慢性静脉功能不全中的内皮功能障碍:一些心血管保护剂的作用。
Angiology. 2009;60(6):763-71. doi: 10.1177/0003319709332108. Epub 2009 Feb 23.
7
Therapeutic angiogenesis for critical limb ischemia: microvascular therapies coming of age.治疗严重肢体缺血的治疗性血管生成:微血管治疗走向成熟。
Circulation. 2008 Jul 1;118(1):9-16. doi: 10.1161/CIRCULATIONAHA.108.784371.
8
Endothelial cell migration during angiogenesis.血管生成过程中的内皮细胞迁移。
Circ Res. 2007 Mar 30;100(6):782-94. doi: 10.1161/01.RES.0000259593.07661.1e.
9
Therapeutic response of rosacea to dobesilate.酒渣鼻对羟苯磺酸钙的治疗反应。
Eur J Med Res. 2005 Oct 18;10(10):454-6.
10
Dobesilate is an angiogenesis inhibitor.羟苯磺酸钙是一种血管生成抑制剂。
Eur J Med Res. 2005 Sep 12;10(9):369-72.